Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2019

01-12-2019 | Research Article

Preventability analysis of adverse drug reactions in a Jordanian hospital: a prospective observational study

Authors: Lama Al Damen, Iman Basheti

Published in: International Journal of Clinical Pharmacy | Issue 6/2019

Login to get access

Abstract

Background Adverse drug reactions remain to be an issue that compromise patient’s safety in Jordan and worldwide. In Jordan, an assessment of factors involved in preventability of adverse drug reactions has not been conducted previously. Objectives To describe the proportion of preventable adverse drug reactions, and the causes of hospital-related preventable adverse reactions in one Jordanian hospital. Methods A prospective observational study of 4 months duration conducted by clinical pharmacists in the hospital. Setting Surgical and medical wards in one Jordanian private hospital. Main outcome measure Proportions of admissions related to adverse drug reactions, proportions of preventable reactions and analysis of the factors involved in the preventable adverse drug reactions. Results Out of 350 admissions recorded during the study period, a total of 38 (10.8%) adverse reactions were detected. Among those, 29 (8.3%) were detected in the hospital and 9 (2.6%) were the cause of the hospital admission. Many (44.7%) of the adverse drug reactions were preventable (31.6% were probably preventable and 13.1% were definitely preventable). About half (55.3%) were unpreventable. Insufficient monitoring was involved in 29.4% of the preventable adverse reactions and inappropriate dosing and drug–drug interactions were independently responsible for 17.6% of the preventable adverse reactions. Conclusion A high proportion of the identified adverse drug reactions were found to be preventable. Insufficient monitoring and inappropriate dosing were the most important factors associated with preventable adverse drug reactions. Nationally, more focused efforts need to be stimulated to prevent preventable adverse drug reactions in hospitals.
Appendix
Available only for authorised users
Literature
2.
go back to reference Rawlins M, Thomson J. Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1991. p. 18–45. Rawlins M, Thomson J. Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1991. p. 18–45.
3.
go back to reference Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38:437–53.CrossRef Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38:437–53.CrossRef
4.
go back to reference Alomar M. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22:83–94.CrossRef Alomar M. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22:83–94.CrossRef
5.
go back to reference Maxwell S. Rational prescribing: the principles of drug selection. Clin Med (Lond). 2016;16:459–64.CrossRef Maxwell S. Rational prescribing: the principles of drug selection. Clin Med (Lond). 2016;16:459–64.CrossRef
6.
go back to reference Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol. 2001;56:935–41.CrossRef Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol. 2001;56:935–41.CrossRef
8.
go back to reference Queneau P, Bannwarth B, Carpentier F, Guliana JM, Bouget J, Trombert B, et al. Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf. 2007;30:81–8.CrossRef Queneau P, Bannwarth B, Carpentier F, Guliana JM, Bouget J, Trombert B, et al. Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf. 2007;30:81–8.CrossRef
9.
go back to reference Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003;12:280–5.CrossRef Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003;12:280–5.CrossRef
10.
go back to reference Olivier P, Boulbes O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice. Drug Saf. 2002;25:1035–44.CrossRef Olivier P, Boulbes O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice. Drug Saf. 2002;25:1035–44.CrossRef
11.
go back to reference Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178:1563–9.CrossRef Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178:1563–9.CrossRef
12.
go back to reference Winterstein AG, Hatton RC, Gonzales-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reactions reports. Am J Health Syst Pharm. 2002;59:1742–9.CrossRef Winterstein AG, Hatton RC, Gonzales-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reactions reports. Am J Health Syst Pharm. 2002;59:1742–9.CrossRef
13.
go back to reference Forster AJ, Worthington JR, Hawken S, Bourke M, Rubens F, Shojania K, et al. Using prospective clinical surveillance to identify adverse events in hospital. BMJ Qual Saf. 2011;20:756–63.CrossRef Forster AJ, Worthington JR, Hawken S, Bourke M, Rubens F, Shojania K, et al. Using prospective clinical surveillance to identify adverse events in hospital. BMJ Qual Saf. 2011;20:756–63.CrossRef
14.
go back to reference Smits M, Zegers M, Groenewegen PP, Timmermans DR, Zwaan L, van der Wal G, Wagner C. Exploring the causes of adverse events in hospitals and potential prevention strategies. Qual Saf Health Care. 2010;19(5):e5.PubMed Smits M, Zegers M, Groenewegen PP, Timmermans DR, Zwaan L, van der Wal G, Wagner C. Exploring the causes of adverse events in hospitals and potential prevention strategies. Qual Saf Health Care. 2010;19(5):e5.PubMed
15.
go back to reference Alsbou M. Incidence of adverse drug reactions in Alkarak Governmental Hospital: a pilot study. J Med. 2010;44(4):444–6. Alsbou M. Incidence of adverse drug reactions in Alkarak Governmental Hospital: a pilot study. J Med. 2010;44(4):444–6.
16.
go back to reference Alsbou M, Alzubiedi S, Alzobi H, Samhadanah NA, Alsaraireh Y, Alrawashdeh O, et al. Adverse drug reactions (ADRs) experience at Al-Karak Teaching Hospital in Jordan. Int J Clin Pharm. 2015;37:1188–93.CrossRef Alsbou M, Alzubiedi S, Alzobi H, Samhadanah NA, Alsaraireh Y, Alrawashdeh O, et al. Adverse drug reactions (ADRs) experience at Al-Karak Teaching Hospital in Jordan. Int J Clin Pharm. 2015;37:1188–93.CrossRef
17.
go back to reference Raut A, Patel PK, Patel CD, Pawar AK. Preventability, predictability and seriousness of adverse drug reactions amongst medicine inpatients in a teaching hospital: a prospective observational study. Int J Pharm Chem Sci. 2012;1:1293–9. Raut A, Patel PK, Patel CD, Pawar AK. Preventability, predictability and seriousness of adverse drug reactions amongst medicine inpatients in a teaching hospital: a prospective observational study. Int J Pharm Chem Sci. 2012;1:1293–9.
20.
go back to reference Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRef Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRef
21.
go back to reference Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting ADRs. Am J Hosp Pharm. 1992;49:2229–32.PubMed Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting ADRs. Am J Hosp Pharm. 1992;49:2229–32.PubMed
22.
go back to reference Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.PubMed Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.PubMed
23.
go back to reference Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a Department of General Medicine. Br J Clin Pharmacol. 1998;45:301–8.CrossRef Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a Department of General Medicine. Br J Clin Pharmacol. 1998;45:301–8.CrossRef
24.
go back to reference Alhamid A, Zoe Aslanpour Z, Aljadhey H, Ghaleb M. Hospitalisation resulting from medicine-related problems in adult patients with cardiovascular diseases and diabetes in the United Kingdom and Saudi Arabia. Int J Environ Res Public Health. 2016;13:479.CrossRef Alhamid A, Zoe Aslanpour Z, Aljadhey H, Ghaleb M. Hospitalisation resulting from medicine-related problems in adult patients with cardiovascular diseases and diabetes in the United Kingdom and Saudi Arabia. Int J Environ Res Public Health. 2016;13:479.CrossRef
25.
go back to reference Aljadhey H, Mahmoud MA, Ahmed Y, Sultana R, Zouein S, Alshanawani S, et al. Incidence of adverse drug events in public and private hospitals in Riyadh, Saudi Arabia: the (ADESA) prospective cohort study. BMJ Open. 2016;6(7):e010831.CrossRef Aljadhey H, Mahmoud MA, Ahmed Y, Sultana R, Zouein S, Alshanawani S, et al. Incidence of adverse drug events in public and private hospitals in Riyadh, Saudi Arabia: the (ADESA) prospective cohort study. BMJ Open. 2016;6(7):e010831.CrossRef
26.
go back to reference Aljadhey H, Mahmoud MA, Mayet A, Alshaikh M, Ahmed Y, Murray MD, et al. Incidence of adverse drug events in an academic hospital: a prospective cohort study. Int J Qual Health Care. 2013;25:648–55.CrossRef Aljadhey H, Mahmoud MA, Mayet A, Alshaikh M, Ahmed Y, Murray MD, et al. Incidence of adverse drug events in an academic hospital: a prospective cohort study. Int J Qual Health Care. 2013;25:648–55.CrossRef
27.
go back to reference Farcas A, Bucsa C, Sinpetrean A, Leucuta D, Mogosan C, Dumitrascu D, et al. Preventability analysis of adverse drug reactions detected in two internal medicine departments in Romania. Intern Emerg Med. 2014;9:187–93.CrossRef Farcas A, Bucsa C, Sinpetrean A, Leucuta D, Mogosan C, Dumitrascu D, et al. Preventability analysis of adverse drug reactions detected in two internal medicine departments in Romania. Intern Emerg Med. 2014;9:187–93.CrossRef
28.
go back to reference Dequito AB, Mol PG, van Doormaal JE, Zaal RJ, van den Bemt PM, Haaijer-Ruskamp FM, et al. Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands. Drug Saf. 2011;34:1089–100.CrossRef Dequito AB, Mol PG, van Doormaal JE, Zaal RJ, van den Bemt PM, Haaijer-Ruskamp FM, et al. Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands. Drug Saf. 2011;34:1089–100.CrossRef
29.
go back to reference Bates DW, Cullen DJ, Laird N. Incidence of adverse drug events and potential adverse drug events: implications for prevention. J Am Med Assoc. 1995;274(1):29–34.CrossRef Bates DW, Cullen DJ, Laird N. Incidence of adverse drug events and potential adverse drug events: implications for prevention. J Am Med Assoc. 1995;274(1):29–34.CrossRef
30.
go back to reference Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm. 2003;60:1750–9.CrossRef Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm. 2003;60:1750–9.CrossRef
Metadata
Title
Preventability analysis of adverse drug reactions in a Jordanian hospital: a prospective observational study
Authors
Lama Al Damen
Iman Basheti
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 6/2019
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00925-0

Other articles of this Issue 6/2019

International Journal of Clinical Pharmacy 6/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine